搜索

Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS

Why Choose Us?

Let China use globally innovative vaccines, and let the world use high-quality vaccines from China!

quanfu quanfu

Strong Corporate Strength

The registered capital is 360 million yuan, the investment in Phase I project is 500 million yuan, the investment in Phase II project is 500 million yuan, and the new investment in Phase III is 2 billion yuan

quanfu quanfu

Products & Services

Committed to the research and development, registration and application, industrial production and sales of innovative vaccines for human use, targeting international standards, and conducting independent innovative research and development.

quanfu quanfu

Scientific Research Capability

Shanghai/Taizhou R&D Center and pilot platform are promoting multiple viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines simultaneously.

Product Pipelines

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Quadrivalent Subunit Influenza Vaccine（0.5ml）

Quadrivalent Subunit Influenza Vaccine（0.5ml）

Quadrivalent Subunit Influenza Vaccine: the components of the 2018-2019 northern hemisphere tetravalent influenza vaccine recommended by WHO are: A / Michigan / 45 / 2015 (H1N1) pdm09 similar strain, a / Singapore / infimh-16-0019 / 2016 (H3N2) similar strain, B / Colorado / 06 / 2017 (Victoria strain) similar strain and B / Phuket / 3073 / 2013 (Yamagata strain).

More Product Series

News Center

Further advances in orthopoxvirus mRNA vaccines
2024-04-12

From April 2 to April 4, 2024, Dr. Xiong Nolin, Deputy General Manager of EW BioTech (Shanghai) Co., Ltd (hereinafter referred to as EW Bio), a wholly-owned subsidiary of Jiangsu Zhonghui Yuantong Bio-Technology Co., Ltd (hereinafter referred to as EW Bio), was invited to participate in the World Vaccine Congress 2024, where he made a keynote speech and exchanged the results of the company's important R & D project of the Orthopoxvirus mRNA vaccine, which was received by the international counterparts with great interest and recognition.
→

Huierkangxin has been selected for the 2024 Jiangsu Province Innovative Pharmaceutical Equipment Special Award List!
2024-03-08

Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (Huier Kangxin), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
→

Received national level praise!
2024-03-01

Recently, recommended by the provincial adverse drug reaction monitoring institutions and comprehensively evaluated by the National Adverse Drug Reaction Monitoring Center, Ab&B Bio-Tech CO., LTD. JS has outstanding performance in fulfilling its main responsibilities in the monitoring of adverse drug reactions in 2023 and has been praised by the National Adverse Reaction Monitoring Center.
→

Have a project？Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search